Neurocrine Biosciences (NASDAQ:NBIX), According to the latest information the short interest in Neurocrine Biosciences, Inc. plummeted by 0.9% or 56,216 shares. The final shorts are 7.2% of the total floated shares. The positions dropped from 6,244,774 shares on May 31,2016 to 6,188,558 on June 15,2016. According to the per-day average trading of 956,750 shares, the days to cover are 6. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Neurocrine Biosciences (NASDAQ:NBIX): The stock opened at $42.20 on Friday but the bulls could not build on the opening and the stock topped out at $44.71 for the day. The stock traded down to $41.56 during the day, due to lack of any buying support eventually closed down at $43.28 with a loss of -2.94% for the day. The stock had closed at $44.59 on the previous day. The total traded volume was 8,931,812 shares.
The company shares have dropped -5.52% from its 1 Year high price. On Nov 27, 2015, the shares registered one year high at $58.46 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $46.49 and the 200 Day Moving Average price is recorded at $44.16.
Neurocrine Biosciences (NASDAQ:NBIX) has tumbled 2.17% during the past week and has dropped 6.3% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.55%. Neurocrine Biosciences (NASDAQ:NBIX) has underperformed the index by 3.46% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.